Research

Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional

by
Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more

Zacks Small Cap Analysis – ACHV: New Skipper on the Helm – Go Well being Professional

by
Zacks Small Cap Analysis – ACHV: New Skipper on the Helm – Go Well being Professional

By John Vandermosten, CFA NASDAQ:ACHV Obtain Life Sciences, Inc. (NASDAQ:ACHV) introduced a shift in its most senior ranks with Richard Stewart reassuming his position as CEO and Thomas King, taking up as Government Chairman. Richard Stewart had beforehand held the CEO position at Obtain altering the mantle of command to John Bencich in Fall of … Read more

The Golden Age of offbeat Arctic analysis – Go Well being Professional

by
The Golden Age of offbeat Arctic analysis – Go Well being Professional

Enlarge / On the US Military’s Camp Century on the Greenland ice sheet, an Military truck geared up with a railroad wheel conversion rides on 1,300 ft of observe below the snow. Lately, the Arctic has develop into a magnet for local weather change anxiousness, with scientists nervously monitoring the Greenland ice sheet for indicators … Read more

Zacks Small Cap Analysis – SCLX Makes Transfer to Increase Shareholder Worth – Go Well being Professional

by

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Firm (NASDAQ:SCLX) is a revenue-generating firm that’s centered on addressing one of many greatest points dealing with humanity in the present day—that of the overuse of opioids. Scilex is targeted on creating non-opioid ache administration merchandise that present the aid sufferers so … Read more

Zacks Small Cap Analysis – CTSO: CytoSorbents Potential for Excessive Margin Income Progress Helps Worth Goal of $4.00 – Go Well being Professional

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 2nd quarter 2024 outcomes on August thirteenth and the outcomes have been principally above our expectations. For the 2nd quarter of 2024, complete revenues elevated roughly 5.0% to $9.9 million. Complete product gross sales have been $8.8 million, a rise of … Read more

x